---
title: "The mainland medical device stock \"Tianxing Medical\" has submitted an application for listing again"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277742801.md"
description: "Chinese medical device company Tianxing Medical has submitted a listing application to the Hong Kong Stock Exchange again, with CITIC Securities and Jianyin International as joint sponsors. The company focuses on sports medicine solutions and is expected to be the fourth largest sports medicine equipment provider in China in terms of sales revenue in 2024, with a market share of 6.5%. In the last nine months, revenue was approximately RMB 273 million, an increase of 23.9%; net profit rose by 47.6% to RMB 89.872 million. The funds raised from the listing will be used to expand production capacity, research and development, marketing, and working capital"
datetime: "2026-03-04T07:24:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277742801.md)
  - [en](https://longbridge.com/en/news/277742801.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277742801.md)
---

# The mainland medical device stock "Tianxing Medical" has submitted an application for listing again

Chinese medical device company Tianxing Medical has submitted its listing application to the Hong Kong Stock Exchange for the second time. According to the preliminary prospectus, the joint sponsors for the company's listing are CITIC Securities and Jianyin International.

Tianxing Medical focuses on clinical solutions for sports medicine. According to data from ZhiShi Consulting, based on sales revenue in 2024, the company is the fourth largest provider of sports medicine equipment in China, with a market share of approximately 6.5% of the Chinese sports medicine implants and devices market, and is also the largest domestic provider of sports medicine equipment.

For the nine months ending in September last year, the company's revenue was approximately RMB 273 million, representing a year-on-year growth of 23.9%; net profit increased by 47.6% to RMB 89.872 million.

Tianxing Medical indicated that the net proceeds from this listing are intended to be used to expand production capacity and improve production efficiency; to support research and development work for patient-oriented product strategies; for commercialization, sales, and marketing activities; and for working capital and general corporate purposes

### Related Stocks

- [301290.CN](https://longbridge.com/en/quote/301290.CN.md)

## Related News & Research

- [Asker Healthcare Group buys Baltic medtech distributor Ambercell Solutions](https://longbridge.com/en/news/296306272.md)
- [What Springer Nature KGaA (XTRA:SPG)'s OpenEvidence AI Integration Means For Shareholders](https://longbridge.com/en/news/296023301.md)
- [Stride Consumer Partners adds Annie Lai, Alexa Tsai as associates](https://longbridge.com/en/news/296027202.md)
- [18:05 ETGreenberg Traurig Chicago Expands Litigation Practice with Addition of Former Federal Prosecutor Prashant Kolluri](https://longbridge.com/en/news/296274474.md)
- [Dental Innovation Alliance executives discuss DSO-driven dentistry shift on ADSO podcast](https://longbridge.com/en/news/296264252.md)